[Radiotherapy and combined therapy in breast cancer: standards and innovations in the adjuvant setting].
Due to the significant advances in the diagnosis and treatment of breast cancer seen in the last decades, increased survival rates and better outcomes of patients are being observed. The role of radiotherapy remains pivotal in the treatment of early breast cancer. In the adjuvant setting, whole breast irradiation remains the standard of care using a relatively well standardized radiation technique. The recent technology advances and 3D conformal radiotherapy allow for better volumes definition resulting to increased organ at risk--sparing and therefore treatment optimization. Sophisticated techniques and emerging options (such as accelerated partial breast irradiation) are not routinely used yet outside of a clinical trial. Moreover, new drugs and targeted therapies have recently been introduced to the clinical practice for treatment individualization according to the specific tumours' prognosis and/or prediction of the drugs' efficacy based on new biological tools. Regarding the synergistic effect of these molecules with ionizing radiation, rigorous prospective evaluation of combined therapy is important to ensure improved long-term benefit/risk ratio. In this review, the significant advances of radiotherapy and combined therapy in the new era of breast cancer management will be discussed.
Service d'oncologie-radiothérapie, CHU Henri-Mondor, AP-HP et faculté de médecine-université de Paris XII, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil cedex, France. belkacemi@chpg.mc
Y
Y
Belkacémi
J
J
Gligorov
M-P
MP
Chauvet
P G
PG
Tsoutsou
H
H
Boussen
C
C
Bourgier
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D047072:Aromatase Inhibitors / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000532:radiotherapy* / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D011379:Prognosis; D011878:Radiotherapy / Q000379:methods / Q000639:trends; D013629:Tamoxifen / Q000627:therapeutic use; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D047072:Aromatase Inhibitors; D013629:Tamoxifen; D000068878:Trastuzumab